KM Research Hub
← 返回论文库
已完成 入排:符合 图源:可得 入排置信度 0.98

Addition of Carboplatin to Sequential Taxane-Anthracycline Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer: A Phase III Randomized Controlled Trial.

Sudeep Gupta, Nita Nair, Rohini W Hawaldar, Shalaka Joshi, Seema Gulia, Tanuja Shet, Rajiv Sarin, Vani Parmar, Sangeeta Desai, Jaya Ghosh, Tabassum Wadasadawala, Vaibhav Vanmali, Tejal Panhale, Pallavi Parab, Asawari Patil, Garvit Chitkara, Sushmita Rath, Jyoti Bajpai, Rima Pathak, Palak Popat, Meenakshi Thakur, Rajendra A Badwe

J Clin Oncol 44(1) 9-19

PMID41115255
PMCIDPMC12736403
DOI10.1200/JCO-25-01023
发表日期2025-10-20
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:KM 曲线已提取;No. at risk 信息待人工复核,不影响当前曲线图像显示。
摘要

摘要

PURPOSE: We evaluated the survival impact of adding platinum to standard taxane-anthracycline neoadjuvant chemotherapy in triple-negative breast cancer (TNBC). METHODS: In this phase III trial, patients with TNBC were randomly assigned, after stratification by stage and menopausal status, to receive neoadjuvant chemotherapy comprising once-per-week carboplatin (AUC-2) plus paclitaxel (100 mg/m2) for 8 weeks, followed by four cycles of anthracycline plus cyclophosphamide, or same chemotherapy without carboplatin. The primary end point was event-free survival (EFS), and secondary end points were overall survival (OS) and pathologic complete response. This is the prespecified primary analysis of this study. RESULTS: Of 720 patients randomly assigned between April 2010 and January 2020, 717 (platinum 361, control 356) were included in modified intention-to-treat analysis. At median follow-up of 67.6 months, in platinum and control arms, there were 111/361 and 131/356 EFS events (hazard ratio [HR], 0.80 [95% CI, 0.62 to 1.03]; two-sided unstratified P = .081), with 5-year EFS of 70.7% (95% CI, 65.8% to 75.6%) and 64.1% (95% CI, 59.0% to 69.2%), respectively, and 94/361 and 121/356 deaths (HR, 0.74 [95% CI, 0.57 to 0.97]; nominal P = .029), with 5-year OS of 74.4% and 66.8%, respectively. In premenopausal patients, EFS (HR, 0.61 [95% CI, 0.43 to 0.84]; nominal P = .003; 5-year EFS 75.0% v 59.6%) and OS (HR, 0.57 [95% CI, 0.40 to 0.82]; nominal P = .002; 5-year OS 78.2% v 64.6%) were significantly higher, while in postmenopausal patients, EFS (HR, 1.19 [95% CI, 0.80 to 1.78]; nominal P = .386) and OS (HR, 1.06 [95% CI, 0.70 to 1.61]; nominal P = .772) were not significantly different, in platinum versus control arm. There was statistically significant interaction between study intervention and menopausal status for EFS and OS, with a benefit of adding platinum in premenopausal but not in postmenopausal patients. There was more grade ≥3 myelosuppression in carboplatin arm, but there was no difference in nonhematologic toxicities. CONCLUSION: Carboplatin did not significantly increase EFS but significantly increased the OS in patients with TNBC, with benefits confined to premenopausal patients.

KM 提取结果

1 个 Figure · 6 个 KM 面板

进入结果中心
KM Figure6 个面板

FIG 2.

FIG 2. Kaplan-Meier estimates for EFS and OS. (A) EFS in the modified intention-to-treat population in the platinum and control arms. (B) EFS in premenopausal patients in the platinum and control arms. (C) EFS in postmenopausal patients in the platinum and control arms. (D) OS in the modified intention-to-treat population in the platinum and control arms. (E) OS in premenopausal patients in the platinum and control arms. (F) OS in postmenopausal patients in the platinum and control arms. All P values are derived from unstratified, two-sided log-rank tests. P values for secondary end points and subgroup analyses are nominal. EFS, event-free survival; OS, overall survival.

A

EFS

FIG 2. · Panel A

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel A 是同一 FIG 2. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
B

EFS

FIG 2. · Panel B

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel B 是同一 FIG 2. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
C

EFS

FIG 2. · Panel C

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel C 是同一 FIG 2. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线 2:short span曲线 2:extreme jump
查看结果
D

OS

FIG 2. · Panel D

quality_warning 待 EXE 对齐 预期 2 条 已提取 1 条

Panel D 是同一 FIG 2. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似重复轨迹:同一条 KM 曲线可能被重复识别曲线缺失:预期 2 条,实际恢复 1 条疑似重复轨迹:同一条 KM 曲线可能被重复识别曲线 1:short span
查看结果
E

OS

FIG 2. · Panel E

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel E 是同一 FIG 2. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线 1:flat topline artifact曲线 2:flat topline artifact
查看结果
F

OS

FIG 2. · Panel F

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel F 是同一 FIG 2. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线 2:short span曲线 2:extreme jump
查看结果
其他 Figure(2,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

FIG 1.FIG 1. CONSORT diagram.
非 KM Figure
FIG 3.FIG 3. Forest plot for EFS and OS. (A) EFS according to subgroups defined by prespecified stratification factors and known prognostic factors. (B) OS according to subgroups defined by prespecified stratification factors and known prognostic factors. The size of the squares corresponds to the number of patients with events. The diamond incorporates the point estimate and the 95% CI of the overall effect. Within-subgroup HRs and 95% CIs are from univariable Cox models; P for interaction is from a two-sided Wald χ 2 test of the treatment-by-subgroup term in a single Cox model. EFS, event-free survival; HR, hazard ratio; LABC, locally-advanced breast cancer; OBC, operable breast cancer; OS, overall survival.
非 KM Figure